GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cyclopharm Ltd (ASX:CYC) » Definitions » EV-to-FCF

Cyclopharm (ASX:CYC) EV-to-FCF : -11.90 (As of Dec. 12, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cyclopharm EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cyclopharm's Enterprise Value is A$154.72 Mil. Cyclopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was A$-13.00 Mil. Therefore, Cyclopharm's EV-to-FCF for today is -11.90.

The historical rank and industry rank for Cyclopharm's EV-to-FCF or its related term are showing as below:

ASX:CYC' s EV-to-FCF Range Over the Past 10 Years
Min: -178.16   Med: -26.15   Max: 481.38
Current: -12.07

During the past 13 years, the highest EV-to-FCF of Cyclopharm was 481.38. The lowest was -178.16. And the median was -26.15.

ASX:CYC's EV-to-FCF is ranked worse than
100% of 78 companies
in the Medical Distribution industry
Industry Median: 17.435 vs ASX:CYC: -12.07

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-12), Cyclopharm's stock price is A$1.645. Cyclopharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.097. Therefore, Cyclopharm's PE Ratio (TTM) for today is At Loss.


Cyclopharm EV-to-FCF Historical Data

The historical data trend for Cyclopharm's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclopharm EV-to-FCF Chart

Cyclopharm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -87.56 -21.50 -46.02 -11.31 -22.45

Cyclopharm Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -11.31 - -22.45 -

Competitive Comparison of Cyclopharm's EV-to-FCF

For the Medical Distribution subindustry, Cyclopharm's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclopharm's EV-to-FCF Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cyclopharm's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Cyclopharm's EV-to-FCF falls into.



Cyclopharm EV-to-FCF Calculation

Cyclopharm's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=154.716/-13
=-11.90

Cyclopharm's current Enterprise Value is A$154.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was A$-13.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclopharm  (ASX:CYC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Cyclopharm's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.645/-0.097
=At Loss

Cyclopharm's share price for today is A$1.645.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.097.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Cyclopharm EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Cyclopharm's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclopharm Business Description

Traded in Other Exchanges
N/A
Address
Unit 4, 1 The Crescent, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.

Cyclopharm Headlines

No Headlines